Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2025-12-24 @ 10:35 PM
NCT ID:
NCT01946035
Eligibility Criteria:
Inclusion Criteria:
* Male or female 18-70 years
* Able to provide informed consent
* Able to comply with the requirements of the protocol
* Diagnosis of allergic rhinitis
* Peak nasal inspiratory flow which is reversible to \>20 l/min with oxymetazoline
* Positive skin prick test to at least one common aeroallergen
* Ability to withhold antihistamines, intranasal corticosteroids for duration of the study
* Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant's well being
Exclusion Criteria:
* Pregnancy, planned pregnancy or lactation
* Respiratory tract infection in the previous 2 months
* Nasal polyps of more than Grade I on nasal endoscopy
* Any known adverse reaction to the Investigational Medicinal Product or other quinazolines
* Systolic BP \<100mmHg
* Any degree of heart block
* Any clinically significant medical condition that may endanger the health or safety of the participant or jeopardise the protocol
* Participation within another clinical trial of investigational medicinal product within the last 30 days
* Under the age of 18
* Benign hyperplasia, chronic urinary tract infections, bladder stones, overflow bladder, anuria or progressive renal failure
* History of oesophageal or gastrointestinal obstruction or decreased lumen diameter of the gastrointestinal tract.
* Concomitant use of PDE5 inhibitors (sildenafil etc.)
* Alpha antagonists - this is the medication under investigation.
* Other cardiovascular medications including but not limited to:
ACE inhibitors, Angiotensin II antagonists, Beta blockers, calcium channel blockers, diuretics, nitrates, phosphodiesterase type-5 inhibitors or other vasodilating medications - these in combination with doxazosin carry an increased risk of symptomatic hypotension.
* Monoamine oxidase inhibitors (MAOIs) - antidepressant medication that can lead to significant hypotension in combination with alpha antagonists.
* Anxiolytics and hypnotics - enhanced hypotensive and sedative effects when alpha-blockers given in combination with these.
* Methyldopa and levodopa - potential enhanced hypotensive effect with alpha antagonists.
* Nasal corticosteroid spray - would confound study outcomes
* Oxymetazoline - this is used as an outcome of response in the study.
* Antihistamines - the participants will be undergoing a histamine nasal challenge.
* Sympathomimetics i.e. dopamine, ephedrine, epinephrine, metaraminol, methoxamine, phenylephrine- may reduce the effect of doxazosin.
* Any other medication, which in the opinion of the Investigator may put the participant at risk.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT01946035
Study Brief:
Protocol Section:
NCT01946035